Associated Papers
Comparative genomic and clinicopathological analysis uncovers contrasting molecular profiles of canine and human thyroid carcinomas.
Das S et al.
Communications Biology, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology.
Echeverría-Garcés G et al.
Frontiers in Pharmacology, 2024
A review of HER2 overexpression and somatic mutations in cancers.
Galogre M et al.
Critical Reviews in Oncology/hematology, 2023
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T et al.
Bmc Cancer, 2023
ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth.
Fan K et al.
Medical Oncology (northwood, London, England), 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS et al.
Bmc Cancer, 2022
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer.
Gaibar M et al.
Journal of Oncology, 2020
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Prevalence and role of HER2 mutations in cancer.
Cocco E et al.
Pharmacology & Therapeutics, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
How is Herstatin, a tumor suppressor splice variant of the oncogene HER2, regulated?
Silipo M et al.
Rna Biology, 2017
Activating HER2 mutations as emerging targets in multiple solid cancers.
Connell CM et al.
Esmo Open, 2017
HER2 mutation status in Japanese HER2-positive breast cancer patients.
Endo Y et al.
Breast Cancer (tokyo, Japan), 2016
Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.
Chumsri S et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2015
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R et al.
Cancer Discovery, 2013
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.
Herter-Sprie GS et al.
Frontiers in Oncology, 2013
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012